The proposed "High Impact Phenotype Identification System" aims to reduce time to diagnosis of 13 high-impact genetic conditions.
Second Genome aims to identify a composite biomarker for the noninvasive diagnosis of nonalcoholic steatohepatitis patients with advanced fibrosis.
The CE-marked version of the kit includes expanded RSV target regions for increased compatibility with commercially available assays.
Lucid Diagnostics said it markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for the early detection of esophageal precancer and cancer.
Basel, Switzerland-based DeepCDR combines deep learning computational methods with a proprietary mammalian display antibody platform.
NHGRI and NCI are supplying the funds over five years to teams at five institutions that have been leading the ClinGen effort since its initial inception in 2013.
The kit chemically treats DNA with bisulfite, a prerequisite for many methylation-based diagnostic tests.
The assay assesses an individual's gut microbiome to provide a report that can guide behavioral and other health interventions to improve gut health.
The partnership with lab partner P4 Diagnostix aims to fast-track liquid biopsy diagnostic tests across pulmonary, metabolic, and women's health diseases.
With ancestry and admixture data from 430 modern-day individuals in Polynesian populations, researchers followed Middle Age migrations to islands in the Pacific.